Thursday's Health Winners & Losers

Avalon Pharmaceuticals is down.
Author:
Publish date:

AtheroGenics

(AGIX)

rose 14% as the company continued to recover from a big loss to start the week. On Monday, its shares tumbled roughly 60% after its heart disease drug failed to meet the main target of a phase III trial. The stock was recently adding 45 cents to $3.67.

Adams Respiratory Therapeutics

(ARXT)

was also surging after the company said it has settled a patent lawsuit over a generic version of Mucinex with Mutual Pharmaceutical and United Research Laboratories. Recently, Adams was climbing $5.17, or 16.8%, to $36.01.

On the downside,

Avalon Pharmaceuticals

(AVRX)

dropped 5.1% after the drugmaker's fourth-quarter loss swelled from the same quarter in the previous year. The stock was off 24 cents at $4.48.

Elsewhere, JPMorgan reduced both

GlaxoSmithKline

(GSK) - Get Report

and

AstraZeneca

(AZN) - Get Report

to underweight from neutral. GlaxoSmithKline was off 1.4% at $55.44, and AstraZeneca was down 1.3% at $55.95.

Also on the move,

ISIS Pharmaceuticals

(ISIS)

was up 7.6% at $10.32.

ImClone Systems

(IMCL)

was rising 4.2% at $34.

Nektar Therapeutics

(NKTR) - Get Report

was gaining 2.4% to $12.44.

Among decliners,

Celgene

(CELG) - Get Report

was off 2.2% at $53.42.

St. Jude Medical

(STJ)

was recently down 1% to $37.99.